Publication: Treatment of Asthma with Drugs Modifying the Leukotriene Pathway
No Thumbnail Available
Open/View Files
Date
1999-01-21
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Massachusetts Medical Society
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Jeffrey M. Drazen, Elliot Israel, and Paul M. O'Byrne. 1999. Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. The New England Journal of Medicine 340, no. 23: 197-206.
Research Data
Abstract
In 1979 and 1980, the chemical structures of the material previously known as slow-reacting substance of anaphylaxis were elucidated as 5(S)- hydroxy- 6(R)-glutathionyl- 7,9-trans-11,14- cis - eico- satetraenoic acid1 and its cysteinyl-glycyl and cysteinyl congener (also known as leukotrienes C4, D4, and E4, respectively). These molecules were so named because the parent molecule was originally isolated from leukocytes, and its carbon backbone contained three double bonds in series, which constitutes a triene. This structural information provided the key to the oxidative pathway of lipid metabolism known as the 5-lipoxygenase pathway.
Description
Other Available Sources
Keywords
General Medicine
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service